In preclinical models, blocking SPP1 or specifically deleting Spp1 in macrophages enhanced the effectiveness of anti‐PD‐1 treatment in mouse liver cancer, resulting in reduced CAFs infiltration and increased cytotoxic T‐cell infiltration. This evidence concerns the gene SPP1 and liver cancer.